Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) – Stock analysts at Leerink Partnrs reduced their FY2025 earnings estimates for MoonLake Immunotherapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($3.22) per share for the year, down from their prior estimate of […]

Leave a Reply

Your email address will not be published.

Previous post Green Plains (NASDAQ:GPRE) Downgraded to Sell Rating by StockNews.com
Next post Walt Disney (NYSE:DIS) Given “Buy” Rating at Rosenblatt Securities